Acomplia Indications To Be Reviewed By Separate FDA Divisions, Sanofi Says

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) will be concurrently reviewed by two separate divisions within FDA's Office of New Drugs, Exec VP-Pharmaceutical Operations Hanspeter Spek said May 13 during the company's earnings call